source scope difference
Product labeling and regimen-level HCV guidance require reconciliation
The retrieved SOVALDI label retains a severe-renal/ESRD limitation while the guideline discusses recommended sofosbuvir-containing regimens in these populations.
What to reconcileHave HCV pharmacy/specialist review the exact regimen and companion drugs. No blended dose is generated.
3 source identities and dates
GlobalRPh RX List - SOVALDIGlobalRPh-hosted RX List | Source revision: Source revision date not established in selected retrieval.
Single-agent SOVALDI sofosbuvir tablets/oral pellets used as part of combination HCV treatment. Not standalone HCV monotherapy or a substitute for fixed-combination labels.
Read this stored source SOVALDI - official product-specific renal limitationDailyMed / Gilead Sciences, Inc. | Source revision: Prescribing information revised December 2024.
SOVALDI - official product-specific renal limitation; selected renal passages, not a complete prescribing monograph.
Read this stored source AASLD-IDSA - recommended HCV regimens in renal impairmentAASLD-IDSA HCV Guidance | Source revision: Current retrieved guidance page; exact page revision date not established.
Recommended HCV regimens in renal impairment. This guideline summary is not a complete antiviral treatment algorithm.
Read this stored source Source-specific interpretation; independent clinician adjudication pending. Added: v5.3.
guideline difference
EPCLUSA: retain current DAA guidance and separate ribavirin rules
AASLD-IDSA records the 2019 regulatory change for sofosbuvir in severe kidney disease/dialysis. Its DAA no-adjustment recommendation does not apply automatically to ribavirin or resolve every liver/renal combined evidence gap.
What to reconcileDo not reuse a historical blanket severe-renal exclusion. Match the complete HCV regimen, hepatic status and any ribavirin requirement.
2 source identities and dates
GlobalRPh RX List - EPCLUSAGlobalRPh-hosted RX List | Source revision: Source revision date not established in selected retrieval.
Selected EPCLUSA renal guidance; regimen duration, liver status, age/weight and ribavirin eligibility still require the full protocol.
Read this stored source Sofosbuvir / velpatasvir - AASLD-IDSA renal guidanceAASLD / IDSA HCV Guidance | Source revision: Source revision date not established in selected retrieval.
AASLD-IDSA HCV guidance for recommended DAA regimens in CKD; not a substitute for liver-stage and regimen eligibility.
Read this stored source Source-specific interpretation; independent clinician adjudication pending. Added: v4.5.
scope and applicability
Fixed-combination renal permission does not remove other eligibility limits
The VOSEVI renal statement belongs to its three-drug combination, with separate hepatic and prior-treatment limitations.
What to reconcileDo not transfer it to every sofosbuvir product or disregard the combination-specific treatment criteria.
1 source identities and dates
GlobalRPh RX List - VOSEVIGlobalRPh-hosted RX List | Source revision: Mirror prints November 2019.
Sofosbuvir / velpatasvir / voxilaprevir - VOSEVI tablets; selected renal passages, not a complete prescribing monograph.
Read this stored source Source-specific interpretation; independent clinician adjudication pending. Added: v5.3.
population formulation scope
Pediatric LS starting-dose ceiling is not the adult tablet cap
The pediatric suspension limits severe-renal dosing to its weight-based starting dose. Adult tablets instead have a uniform severe-renal cap. Both retrieved sources print indexed clearance units, which must remain visible.
What to reconcileMatch age, neurogenic indication, weight, concentration, product and renal method. Do not apply the adult ceiling uniformly to a small child or substitute adult unindexed estimates without reconciliation.
1 source identities and dates
GlobalRPh RX List - VESIcare LSGlobalRPh-hosted RX List | Source revision: Source revision date not established in selected retrieval.
VESICARE LS 1 mg/mL for pediatric neurogenic detrusor overactivity, age two years and older.
Read this stored source Source-specific interpretation; independent clinician adjudication pending. Added: v4.0.
scope and applicability
Keep the renal titration interval with the renal maximum
The moderate-impairment schedule uses at least seven days before an increase. This is not the general three-day titration schedule.
What to reconcileReview the source-specific interval, maximum, indexed eGFR and monitoring together.
2 source identities and dates
GlobalRPh RX List - SUNOSIGlobalRPh-hosted RX List | Source revision: Source revision date not established in selected retrieval.
Solriamfetol - SUNOSI oral tablets; selected renal passages, not a complete prescribing monograph.
Read this stored source SUNOSI - official renal dose and monitoring checkDailyMed / Axsome Therapeutics, Inc. | Source revision: Prescribing information revised May 2026.
SUNOSI - official renal dose and monitoring check; selected renal passages, not a complete prescribing monograph.
Read this stored source Source-specific interpretation; independent clinician adjudication pending. Added: v5.3.
study vs instruction
Trial enrollment limits are not a new dose algorithm
The selected source distinguishes studied renal ranges, trial discontinuation rules and volume-related adverse events.
What to reconcileKeep trial observations separate from prescribing restrictions; assess a different renal trajectory rather than labeling every change expected.
1 source identities and dates
GlobalRPh RX List - INPEFAGlobalRPh-hosted RX List | Source revision: Source revision date not established in selected retrieval.
Sotagliflozin - INPEFA tablets; selected renal passages, not a complete prescribing monograph.
Read this stored source Source-specific interpretation; independent clinician adjudication pending. Added: v5.3.
formulation and source limit
Suspension non-equivalence and an incompletely specified renal starting instruction
The suspension is not therapeutically equivalent to ALDACTONE tablets. Its renal sentence gives a starting amount without a distinct frequency.
What to reconcileDo not import a tablet alternate-day schedule. Resolve the frequency in the exact product and indication context.
2 source identities and dates
GlobalRPh RX List - CAROSPIRGlobalRPh-hosted RX List | Source revision: Source revision date not established in selected retrieval.
CAROSPIR spironolactone oral suspension 25 mg/5 mL; adult heart-failure renal initiation context. Not ALDACTONE tablets.
Read this stored source CAROSPIR - official formulation and renal monitoring checkDailyMed / CMP Pharma, Inc. | Source revision: Prescribing information revised September 2023.
CAROSPIR - official formulation and renal monitoring check; selected renal passages, not a complete prescribing monograph.
Read this stored source Source-specific interpretation; independent clinician adjudication pending. Added: v5.3.
drug versus chelate removal
Removal of drug is not equivalent to removal of lead chelates
The selected official and mirror sections distinguish drug dialyzability from chelate removal.
What to reconcileKeep toxicology assessment and monitoring attached. Do not derive a dialysis supplement from removal information alone.
2 source identities and dates
GlobalRPh RX List - CHEMETGlobalRPh-hosted RX List | Source revision: Source revision date not established in selected retrieval.
CHEMET oral succimer for its pediatric lead-poisoning indication; not prophylaxis or treatment of lead encephalopathy.
Read this stored source CHEMET - succimer capsulesDailyMed / Recordati Rare Diseases Inc. | Source revision: 9/2024
CHEMET oral succimer for its pediatric lead-poisoning indication; not prophylaxis or treatment of lead encephalopathy.
Read this stored source Source-specific interpretation; independent clinician adjudication pending. Added: v5.8.
qualitative accumulation precaution
Low absorption does not eliminate aluminum accumulation risk
Renal failure and dialysis can impair elimination of absorbed aluminum. No specific renal reduction is supplied.
What to reconcileReview aluminum exposure and toxicity precautions; do not label this product universally free of renal concerns.
1 source identities and dates
GlobalRPh RX List - CARAFATE suspensionGlobalRPh-hosted RX List | Source revision: Source revision date not established in selected retrieval.
CARAFATE oral suspension; aluminum-related renal safety, not a renal dose-reduction table.
Read this stored source Source-specific interpretation; independent clinician adjudication pending. Added: v5.7.
timing and restriction
Waiting to re-block is not redosing the reversal drug
Renal precautions affect subsequent blockade as well as reversal eligibility.
What to reconcileUse anesthesia-led ventilation and neuromuscular monitoring; distinguish blocker doses from BRIDION doses.
1 source identities and dates
GlobalRPh RX List - BRIDIONGlobalRPh-hosted RX List | Source revision: Source revision date not established in selected retrieval.
BRIDION reversal of rocuronium/vecuronium neuromuscular blockade. Dose selection depends on blockade depth; this is not an anesthesia dosing calculator.
Read this stored source Source-specific interpretation; independent clinician adjudication pending. Added: v5.6.
source ambiguity
Exact-130 threshold differs between printed sources
At CrCl exactly 130 mL/min, the printed UCSF band uses a six-hour interval; the official label places 130 in the four-hour band.
What to reconcileDo not average these intervals. Confirm current labeling and the local protocol before clinical use.
2 source identities and dates
XACDURO - sulbactam/durlobactam injectionDailyMed / NLM; manufacturer prescribing information | Source revision: Prescribing information revised May 2023; DailyMed page updated November 26, 2025.
Adults at least 18 years old; HABP/VABP caused by susceptible Acinetobacter baumannii-calcoaceticus complex.
Read this stored source UCSF - sulbactam/durlobactam renal and HD regimensUCSF Infectious Diseases Management Program | Source revision: Revision date not established in selected retrieval.
Adult IV sulbactam/durlobactam; restricted to infectious-disease/antimicrobial-stewardship approval for carbapenem-resistant Acinetobacter infections.
Read this stored source Source difference identified; final patient-specific adjudication required. Added: vearlier.
population scope
ORLYNVAH: no adjustment is not sufficient prescribing eligibility
The renal range does not expand the limited-alternative uncomplicated-UTI indication or remove uric-acid-stone and interaction contraindications.
What to reconcileConfirm indication, population, dialysis status, kidney-stone history and interacting drugs.
2 source identities and dates
GlobalRPh RX List - ORLYNVAHGlobalRPh-hosted RX List | Source revision: RX page prints March 2025.
Sulopenem etzadroxil / probenecid - ORLYNVAH tablets; selected source sections only, not a complete prescribing monograph.
Read this stored source ORLYNVAH - official renal prescribing summaryDailyMed / Iterum Therapeutics | Source revision: Prescribing information revised December 2025.
ORLYNVAH - official renal prescribing summary; selected source sections only, not a complete prescribing monograph.
Read this stored source Source-specific interpretation; independent clinician adjudication pending. Added: v4.9.
pharmacokinetics only
A PK finding is not a complete renal dosing recommendation
No significant exposure difference in the studied range does not establish a severe-renal or dialysis regimen.
What to reconcileKeep this card labeled PK-only and retain the unstudied range.
1 source identities and dates
GlobalRPh RX List - ZEGFROVYGlobalRPh-hosted RX List | Source revision: Source revision date not established in selected retrieval.
Sunvozertinib - ZEGFROVY tablets; selected renal passages, not a complete prescribing monograph.
Read this stored source Source-specific interpretation; independent clinician adjudication pending. Added: v5.3.
ambiguous threshold
Exactly 15 is written differently in the dosing and PK sections
Section 8.7 uses below 15 for avoidance and above 15 for usual dosing; the PK analysis includes at least 15. Exactly 15 is therefore not consistently assigned across the selected sections.
What to reconcileSeek exact-label clarification at this endpoint. Do not round, silently change an inequality, or apply indexed eGFR when the source uses a BSA-adjusted measure.
1 source identities and dates
Suzetrigine (JOURNAVX, adults)DailyMed / Vertex Pharmaceuticals Incorporated | Source revision: January 2026
Adult oral JOURNAVX acute pain; exact Vertex label; not pediatric or dialysis dosing.
Read this stored source Source-specific interpretation; independent clinician adjudication pending. Added: v3.6.
boundary reconciliation
Exact eGFR boundary remains unresolved in both sources
The official recheck retains the same greater-than versus greater-than-or-equal boundary distinction seen in the mirror.
What to reconcileDo not assign exact 15 from the PK paragraph or change absolute mL/min to indexed units. Obtain product-specific clarification.
2 source identities and dates
GlobalRPh RX List - JOURNAVXGlobalRPh-hosted RX List | Source revision: Source revision date not established in selected retrieval.
Suzetrigine - JOURNAVX adult oral tablets; selected renal passages, not a complete prescribing monograph.
Read this stored source JOURNAVX - official renal boundary and measure recheckDailyMed / Vertex Pharmaceuticals Incorporated | Source revision: Prescribing information revised January 2026.
JOURNAVX - official renal boundary and measure recheck; selected renal passages, not a complete prescribing monograph.
Read this stored source Source-specific interpretation; independent clinician adjudication pending. Added: v5.3.
boundary and indication
PAH scope and an unassigned exact CrCl boundary
The source uses PAH-specific daily instructions and leaves an exact boundary unstated in its numeric dosage bands.
What to reconcileDo not insert an ED schedule or silently interpolate the boundary. Obtain product-specific clarification.
1 source identities and dates
GlobalRPh RX List - ADCIRCAGlobalRPh-hosted RX List | Source revision: Source revision date not established in selected retrieval.
ADCIRCA tablets for WHO Group 1 pulmonary arterial hypertension; not as-needed erectile dysfunction or a fixed-combination tadalafil product.
Read this stored source Source-specific interpretation; independent clinician adjudication pending. Added: v5.4.